ReviewHuman vaccines & immunotherapeutics2025
Cost-effectiveness analyses of 20-valent pneumococcal conjugate vaccine in children and adults: A narrative review.
Review in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many pneumococcal vaccines have been developed. Economic evaluation provides a framework to inform decision-making. Cost-effectiveness analysis (CEA) studies on 20-valent pneumococcal conjugate vaccine (PCV20) have been published. We introduce the concept of health economics and the basic framework for CEAs. We present a narrative literature review of recent CEA studies involving the PCV20. We also provide guidance for interpreting vaccine-related CEAs. We included 26 CEAs (17 in adults, nine in children) from 15 countries in this review. Eight of the pediatric studies and 11 of the adult studies concluded that PCV20 strategy would be cost-saving compared with existing vaccine(s), in at least one comparison. CEA is a modeling method based on existing data but includes a degree of uncertainty. It is therefore important to interpret the results of a CEA study with an understanding of the features and limitations of the analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.